NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹32 Cr | ₹6.32 Cr | ₹6.24 Cr | ₹8.06 Cr | ₹11 Cr |
What is the latest Total Non-Current Liabilities ratio of NGL FINECHEM ?
Year | Total Non-Current Liabilities |
---|---|
Mar2025 | ₹32 Cr |
Mar2024 | ₹6.32 Cr |
Mar2023 | ₹6.24 Cr |
Mar2022 | ₹8.06 Cr |
Mar2021 | ₹11 Cr |
How is Total Non-Current Liabilities of NGL FINECHEM Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹32 Cr | 406.36 | |
Mar2024 | ₹6.32 Cr | 1.27 | |
Mar2023 | ₹6.24 Cr | -22.60 | |
Mar2022 | ₹8.06 Cr | -27.82 | |
Mar2021 | ₹11 Cr | - |
Compare Total Non-Current Liabilities of peers of NGL FINECHEM
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NGL FINECHEM | ₹880.8 Cr | -5.4% | 16.7% | -34.8% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹386,197.0 Cr | 0.9% | -0.2% | -12.5% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,634.0 Cr | 0.1% | 0.4% | 16.6% | Stock Analytics | |
CIPLA | ₹126,082.0 Cr | 0.5% | 3.8% | -3.5% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹121,167.0 Cr | NA | -0.9% | 4.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹108,783.0 Cr | 2.8% | 6.9% | -2% | Stock Analytics |
NGL FINECHEM Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | -5.4% |
16.7% |
-34.8% |
SENSEX | 1% |
2.1% |
0.5% |
You may also like the below Video Courses